About this trial

Patients with suspected or proven sigmoid colon adenocarcinoma, eligible for curative treatment whose MRI can be reviewed prior to surgery and has no decision regarding radical treatment are eligible. Patient are randomised to the control arm which the standard care of preoperative CT imaging and subsequent discussion by the Multidisciplinary Team or the interventional arm which has the additional use of MRI imaging and subsequent discussion by the Multidisciplinary Team. Patients are followed up at 1 and 3 years together with QoL questionnaires.

Eligibility criteria

Qualifiers

Have a suspected or proven sigmoid colon adenocarcinoma

Is eligible for curative treatment

Has no irresectable metastatic disease

MRI can be reviewed by an MDT prior to surgery

Disqualifiers

Have metastatic disease (including resectable liver metastases)

Have a synchronous second malignancy

Are contraindicated for MRI

Are contraindicated for or have allergy to Buscopan (e.g. glaucoma, small or large bowel obstruction, GFR<30)

Trial design

Treatments tested in this trial

  • Preoperative MRI scan

Treatment groups

244 Participants
are divided into 3 treatment groups

Locations

16
Cambridgeshire
Hinchingbrooke HospitalPE29 6NT, Huntingdon United Kingdom
Cheshire
Leighton HospitalCW1 4QJ, Crewe United Kingdom
County Durham
University Hospital of North TeesTS19 8PE, Stockton-on-Tees United Kingdom
Croydon
Croydon University HospitalCR7 7YE, Thornton Heath United Kingdom

Sponsors and collaborators

Imperial College London

Lead sponsor

Pelican Cancer Foundation

Collaborator